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Mendelian randomization shows a causal
effect of low vitamin D on multiple
sclerosis risk
ABSTRACT
Objective: We sought to estimate the causal effect of low serum 25(OH)D on multiple sclerosis
(MS) susceptibility that is not confounded by environmental or lifestyle factors or subject to
reverse causality.
Methods: We conducted mendelian randomization (MR) analyses using an instrumental variable
(IV) comprising 3 single nucleotide polymorphisms found to be associated with serum 25(OH)D
levels at genome-wide significance. We analyzed the effect of the IV on MS risk and both age
at onset and disease severity in 2 separate populations using logistic regression models that
controlled for sex, year of birth, smoking, education, genetic ancestry, body mass index at age
18–20 years or in 20s, a weighted genetic risk score for 110 known MS-associated variants,
and the presence of one or more HLA-DRB1*15:01 alleles.
Results: Findings from MR analyses using the IV showed increasing levels of 25(OH)D are associ-
ated with a decreased risk ofMS in both populations. In white, non-Hispanic members of Kaiser Per-
manente Northern California (1,056 MS cases and 9,015 controls), the odds ratio (OR) was 0.79
(p5 0.04, 95% confidence interval (CI): 0.64–0.99). In members of a Swedish population from the
Epidemiological Investigation of Multiple Sclerosis and Genes and Environment in Multiple Sclero-
sis MS case-control studies (6,335 cases and 5,762 controls), the OR was 0.86 (p 5 0.03, 95%
CI: 0.76–0.98). A meta-analysis of the 2 populations gave a combined OR of 0.85 (p 5 0.003,
95% CI: 0.76–0.94). No association was observed for age at onset or disease severity.
Conclusions: These results provide strong evidence that low serum 25(OH)D concentration is
a cause of MS, independent of established risk factors. Neurol Genet 2016;2:e97; doi: 10.1212/
NXG.0000000000000097
GLOSSARY
CI 5 confidence interval; EHR 5 electronic health record; EIMS 5 Epidemiological Investigation of Multiple Sclerosis;
GERA 5 Genetic Epidemiology Research on Adult Health and Aging; GEMS 5 Genes and Environment in Multiple Sclerosis;
GWAS 5 genome-wide association study; HWE 5 Hardy-Weinberg equilibrium; ICD-9 5 International Classification of
Diseases, 9th Revision; IV 5 instrumental variable; KPNC 5 Kaiser Permanente in Northern California; LD 5 linkage disequi-
librium; MAF 5 minor allele frequency; MDS 5 multidimensional scaling; MR 5 mendelian randomization; MS 5 multiple
sclerosis;MSSS 5 Multiple Sclerosis Severity Scores; SNP 5 single nucleotide polymorphism; VDRE 5 vitamin D response
element; wGRS 5 weighted genetic risk score.
Multiple sclerosis (MS) is an immune-mediated, demyelinating disease that leads to a wide vari-
ety of symptoms and disability. Both genetic and environmental factors have been implicated in
its etiology, including vitamin D deficiency. Observational studies have consistently shown an
association of low serum 25(OH)D and increased risk of MS, but it has not been shown that low
25(OH)D is actually a cause of MS.1 The apparent beneficial effects of 25(OH)D on MS might
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alternately be explained by reverse causation
(i.e., MS could be leading to low 25(OH)D)
or by confounding by sun exposure, obesity,
or some other unknown factors.
Mendelian randomization (MR), equiva-
lently, instrumental variable (IV) analysis
using a genetic instrument, is a technique that
can overcome the problems of both reverse
causation and confounding when assessing
the causal relationship between an exposure
and an outcome.2 Single nucleotide polymor-
phisms (SNPs) known to be associated with
25(OH)D levels, rather than measured 25
(OH)D, can be used as an IV to estimate
the effect of low 25(OH)D on MS. Because
SNP genotypes are determined at birth and are
not likely to be influenced by potential con-
founding variables, the effect estimate from
MR analysis should not be confounded, and
reverse causation is unlikely because MS does
not determine which 25(OH)D-associated
SNPs are inherited (figure). We used MR
analysis to estimate the causal relationship
between serum 25(OH)D levels and MS sus-
ceptibility in 2 large case-control studies. We
also investigated 2 clinical phenotypes for MS:
age at onset and disease severity.
METHODS KPNC participants. Data were collected from
members of Kaiser Permanente Medical Care Plan, Northern
California Region (KPNC). KPNC is an integrated health service
delivery system with a membership of 3.2 million that comprises
about 25–30% of the population of a 22-county service area and
is the largest health care provider in northern California.
Membership is largely representative of the general population
in the service area; however, persons in impoverished
neighborhoods are underrepresented.3
Eligible KPNC cases were defined as individuals with a diag-
nosis of MS by a neurologist (ICD-9 code 340.xx), age 18–69
years, and membership in KPNC at initial contact. The study was
restricted to self-identified white (non-Hispanic) race/ethnicity,
the population with the highest prevalence of MS. The treating
neurologist was contacted for approval to contact each case as
a potential MS study participant. A total of 3,293 potential MS
cases were reviewed by KPNC neurologists, who approved con-
tact with 2,823 (86%) at the time of the data freeze (August
2014). Diagnoses were validated using electronic health record
(EHR) review and according to published diagnostic criteria.4
Multiple Sclerosis Severity Scores (MSSS) were calculated for
each case at the time of study entry (mean disease duration 5
17.7 years), as described,5 and participants were asked to recall the
age of first MS symptom onset which was validated using EHR
data when possible.
Controls were white (non-Hispanic) current KPNCmembers
without a diagnosis of MS or related condition (optic neuritis,
transverse myelitis, or demyelinating disease; ICD-9 codes: 340,
341.0, 341.1, 341.2, 341.20, 341.21, 341.22, 341.8, 341.9,
377.3, 377.30, 377.39, and 328.82) confirmed through EHR
data. Potential study participants were contacted by email with
a follow-up phone call. The participation rate was 80% for cases
and 66% for controls. Genetic data were available for approxi-
mately 80% of study participants.
Additional controls were individuals of the Genetic Epidemiol-
ogy Research on Adult Health and Aging (GERA) cohort partici-
pating in the KPNC Research Program on Genes, Environment,
and Health, which is described elsewhere (dbGaP phs000674.v2.
p2).6,7 Respondents completed a written consent form and provided
a saliva sample for DNA extraction. A total of 110,266 participant
samples were initially collected. Approximately 103,000 samples
were successfully genotyped, and 77% of participants subsequently
returned new consent forms for placement in dbGaP (NIH), re-
sulting in a final sample size of 78,486 participants. From these
Figure Relationship of exposure, outcome, confounding variables, and genetic instrumental variable used in
mendelian randomization
IV 5 instrumental variable; SNP 5 single nucleotide polymorphism.
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participants, we selected a subset of 12,605 self-reported non-
Hispanic white individuals matched to MS cases for sex and age
(62 years) at a 10:1 ratio.
EIMS/GEMS participants. Data were collected from 2
population-based case-control studies on incident MS patients
(the Epidemiological Investigation of Multiple Sclerosis [EIMS]
study) and prevalent MS patients (the Genes and Environment
in Multiple Sclerosis [GEMS] study). In the EIMS study, the
inclusion criteria were age 16–70 years, recently (within 2 years)
diagnosed MS according to the McDonald criteria,4 and ability to
understand Swedish. For the GEMS study, the participants were
identified from the Swedish National MS registry and recruited
during 2009–2011. In both studies, controls (without MS) were
randomly chosen from the population register and matched to the
patients with MS by sex, age at inclusion in the study, and region of
residence (2 controls per case in EIMS and 1 control per case in
GEMS). Information on age at onset was self-reported. Data on
MSSS5 were retrieved from the Swedish NationalMS registry for all
participants, in both EIMS and GEMS studies as per September
2014 (mean disease duration 5 20.1 years). All participants in the
EIMS study were distinct from those in the GEMS study. Details
of the study design have been described elsewhere.8,9 The
participation rate was 92% for cases and 67% for controls in
EIMS, and 82% for cases and 66% for controls in GEMS.
Genotyping data were available for 75% of EIMS and 91% of
GEMS participants.
Standard protocol approvals, registrations, and patient
consents. Study protocols for KPNC participants were approved
by the Institutional Review Boards of KPNC and the University
of California, Berkeley. Ethical approval for both EIMS and
GEMS was obtained from the Regional Ethical Review Board
in Stockholm at Karolinska Institutet, and participants provided
written informed consent.
Exposure assessment in KPNC. KPNC participants com-
pleted a computer-assisted telephone interview comprised
questions related to various events and exposures, as described
elsewhere.10,11 GERA controls were mailed a survey consisting
of questions related to health behaviors, sociodemographic
information, and diagnoses (dbGaP phs000674.v2.p2).
Whole blood was collected and processed using the Gentra
Puregene protocol. Saliva was collected using Oragene kits.
Medium resolutionHLA-DRB1 and genome-wide SNP genotyp-
ing were performed as previously described12,13 using Illumina
Infinium 660K and Human Omni Express BeadChip arrays for
KPNC cases and controls, and Axiom (Affymetrix) custom chips
for the additional GERA controls. SNPs with a minor allele
frequency (MAF) ,1%, success rate ,90%, or not in Hardy-
Weinberg equilibrium (HWE) among controls (p , 0.000001)
were removed from analysis. Samples with.10% failed genotype
calls and related individuals were also removed. Imputation
against reference haplotypes from Phase I of the 1000 Genomes
Project was conducted using SHAPEIT and IMPUTE2. To
ensure high-quality imputation results, only SNPs with info score
.0.8 on all 3 genotyping platforms and with MAF in controls
with SD ,0.03 across all 3 platforms were retained for analysis.
Cross-platform association tests were conducted to remove SNPs
associated with the genotype array (FDR q , 0.05). Population
outliers were identified using multidimensional scaling (MDS)
and removed from analysis. Two MDS components were used
to adjust for population stratification due to genetic ancestry
differences between cases and controls in the association analysis.
Exposure assessment in EIMS and GEMS. The exposure
assessment was done through an extensive questionnaire that cov-
ered demographic and environmental factors; details are described
elsewhere.8,9 Participants were asked to provide blood samples,
which were genotyped on an Illumina custom array (MS replica-
tion chip).HLA-DRB1 information was imputed with a modified
version of HLA*IMP:0214 with 400 Swedish controls added to
the reference panel for MHC class II genes. SNPs with ,2%
MAF, success rate ,98%, or not in HWE among controls (p ,
0.0001) were removed from analysis. Individuals with .2%
failed genotype calls, with increased heterozygosity (.mean 1
2SD), related individuals, or whose recorded sex differed from
genotype were removed from analysis. We removed population
outliers identified using the smartpca program15 with standard
settings using 3,736 ancestry informative markers. Two principal
component analysis vectors, those with p ,0.05, were used to
adjust for population stratification in the association analysis,
similar to KPNC comparisons described above.
Statistical analyses. A 25(OH)D IV was constructed for each
individual using the b coefficients for 3 published genetic variants
associated at genome-wide significance with higher serum 25(OH)
D: rs2282679-A, in an intron of GC; rs2060793-A, upstream of
CYP2R1; and rs3829251-G, in an intron of NADSYN1 and
upstream of DHCR7.16 The IV was calculated by multiplying the
number of alleles that correspond to an increase in 25(OH)D for
each locus by the b coefficient from the genome-wide association
study (GWAS) for that variant and then taking the sum across the
3 loci (table 1). For KPNC, either the genotyped alleles or imputed
allele probabilities were used to calculate the IV. For EIMS/GEMS,
genotyped alleles were used to calculate the IV, and missing
genotypes (2 for rs2282679 and 243 for rs3822951) were
replaced with 2 times the MAF. In addition, rs10741657, which
is in perfect linkage disequilibrium (LD) with rs2060793 (r25 1 in
1,000 Genomes Phase I European population), was used in the IV
calculation for EIMS/GEMS, as the latter SNP was not genotyped.
A weighted genetic risk score (wGRS) for 110 non-HLA MS
susceptibility loci identified through the most recent MS GWAS
Table 1 Characteristics of SNPs used to construct the 25(OH)D instrumental variable
SNP
Allele associated with
increasing 25(OH)D
Allele
frequency Chromosome Gene
Weight (b coefficient from
GWAS of serum 25(OH)D)
rs2282679 A 0.74 4 GC 0.38
rs2060793; rs10741657 A; A 0.41 11 CYP2R1 0.25
rs3829251 G 0.81 11 NADSYN1/DHCR7 0.18
Abbreviations: EIMS 5 Epidemiological Investigation of Multiple Sclerosis; GEMS 5 Genes and Environment in Multiple Sclerosis; GWAS 5 genome-wide
association study; KPNC 5 Kaiser Permanente in Northern California; SNP 5 single nucleotide polymorphism.
The 2 SNPs near the CYP2R1 gene are in linkage disequilibrium in European populations; rs2060793 was used in KPNC, and rs10741657 was used in
EIMS/GEMS. Allele frequencies are those reported in the 25(OH)D GWAS.
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was calculated for each individual.17 The wGRS was calculated by
multiplying the number of risk alleles for each locus by the
logarithm of the odds ratio (OR) for that variant, then taking the
sum across the 110 loci. One SNP was missing for KPNC
(rs201202118), and 2 SNPs were missing for EIMS/GEMS
(rs2028597 and rs6874308).
After quality control and removal of population outliers,
1,655 individuals from KPNC (1,056 cases and 599 controls)
with genetic data were available as well as an additional 8,416
controls from the GERA study, for a total of 1,056 cases and
9,015 controls. Data for 6,335 cases and 5,762 controls were
available from the Swedish studies (EIMS and GEMS).
Demographic differences between cases and controls were
compared using x2 and independent sample t tests where appro-
priate. Linear regression was used to test the assumption that the
IV is not associated with confounding factors. MR analysis, in
this case a separate-sample IV analysis, was performed by regress-
ing MS case status on the 25(OH)D IV in logistic models, and
regressing MSSS and age at onset on the 25(OH)D IV in linear
regression models. All analyses were controlled for sex, year of
birth, ever smoking, college education,HLA-DRB1*15:01 carrier
status, wGRS of non-HLA MS risk variants, and genetic ancestry
(as derived from the first 2 components from MDS for KPNC or
smartpca for Sweden). Swedish analyses were additionally con-
trolled for region of residency and study type (EIMS vs GEMS).
Matching variables were included as covariates because the final
study populations included all participants with genotyping data
available, and a matched analysis was not performed. ORs with
95% confidence intervals (CIs) were estimated. Meta-analysis
assuming random effects was performed.
All analyses were conducted using PLINK,18 STATA (Stata-
Corp, College Station, TX), SAS (SAS Institute, Cary, NC), or R.19
RESULTS Demographic and disease characteristics of
MS cases and controls are found in table 2 for both
KPNC and Sweden studies. There were significant
differences between cases and controls with respect to
smoking, college graduation, obesity at age 18–20
years or in 20s, and HLA-DRB1*15:01 status for both
KPNC and EIMS/GEMS, as expected, and for age and
sex in EIMS/GEMS. The 25(OH)D IV was lower
among cases than that in controls in KPNC (1.026
vs 1.045, respectively; p 5 0.049) and in EIMS/
GEMS (1.044 vs 1.056, respectively; p 5 0.043).
In both KPNC and EIMS/GEMS, the IV was not
associated with year of birth, sex, smoking, college
education, obesity at age 18–20 years or in 20s,
HLA-DRB1*15:01 status, or the wGRS of 110 non-
HLA MS risk variants, or with study type in the
Swedish population. In EIMS/GEMS, it was
associated with 2 of the 6 geographic regions.
The 25(OH)D IV was associated with MS suscep-
tibility after controlling for sex, year of birth, ancestry,
smoking, wGRS of 110 non-HLA MS risk variants,
and number of HLA-DRB1*15:01 alleles, as well as
study type and region of residency in the Swedish
study. An increasing IV score corresponding to
increasing 25(OH)D levels was protective against
MS (OR 0.79, 95% CI: 0.64–0.99; p 5 0.04) in
the KPNC study. An association was also found for
the Swedish study (OR 0.86, 95% CI: 0.76–0.98;
p 5 0.03). Adjustment did not alter the findings sub-
stantially; however, for both KPNC and EIMS/GEMS
data sets, p values and ORs were both lower in the full
models compared with those in the unadjusted models
(data not shown). Expanded models are shown for
KPNC (table e-1 at Neurology.org/ng) and EIMS/
GEMS (table e-2). Both studies were combined into
a meta-analysis: the association remained (OR 0.85,
95% CI: 0.76–0.94; p 5 0.003). No evidence of
Table 2 Population characteristics for the KPNC and EIMS/GEMS study participants
Characteristic
KPNC MS cases
(N 5 1,056)
KPNC controls
(N 5 9,015) p Value
EIMS/GEMS MS
cases (N 5 6,335)
EIMS/GEMS controls
(N 5 5,762) p Value
Females:males 841:215 7,328:1,687 0.196 4,162:1,723 4,378:1,384 ,0.001
Year of birth 1958 6 8.8 1958 6 8.9 0.246 1960 6 13.1 1961 6 13.3 0.021
Body mass indexa 23.0 6 4.4 21.5 6 3.3 ,0.001 22.0 6 3.5 21.7 6 3.2 ,0.001
College graduate ,0.001 0.002
Yes 468 (44) 3,141 (35) 4,521 (71) 3,963 (69)
No 588 (56) 5,874 (65) 1,814 (29) 1,799 (31)
Smoker ,0.001 ,0.001
Ever 525 (50) 2,876 (32) 3,578 (56) 2,742 (48)
Never 531 (50) 6,139 (68) 2,757 (44) 3,020 (52)
HLA-DRB1*15:01 ,0.001 ,0.001
0 copies 498 (47) 6,613 (73) 2,615 (41) 4,095 (71)
1–2 copies 558 (53) 2,402 (27) 3,720 (59) 1,667 (29)
Abbreviations: EIMS 5 Epidemiological Investigation of Multiple Sclerosis; GEMS 5 Genes and Environment in Multiple Sclerosis; KPNC 5 Kaiser Perma-
nente in Northern California; MS 5 multiple sclerosis.
Values are mean 6 SD or N (%). p Values for differences between cases and controls are from Student t tests or x2 tests.
a At age 18 years or in 20s (KPNC), or at age 20 years (EIMS/GEMS).
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heterogeneity between populations was observed (I25
0.0%, heterogeneity x2 p5 0.51). Results are summa-
rized in table 3. The 25(OH)D IV was not associated
with MSSS or age at onset in either study (data not
shown).
Validating additional assumptions. To test the MR
model assumptions for the 25(OH)D IV, we con-
ducted overidentification tests to evaluate the null
hypothesis that effect estimates from multiple IVs
are identical.20 Each variant was split into a separate
instrument. Estimates suggested the same direction of
causal effect, with ORs ranging from 0.92 to 0.94 in
KPNC and 0.84 to 0.99 in EIMS/GEMS (table 4).
DISCUSSION This study, using data from 2 differ-
ent populations, provides strong evidence that low
25(OH)D is causally associated with MS susceptibil-
ity. Numerous observational studies have shown an
association between low serum 25(OH)D level and
increased risk of MS, and some have provided evi-
dence supporting a causal association. In a study that
examined patients with clinically isolated syndrome,
a first event suggestive of MS, low 25(OH)D levels
early in the disease course predicted higher MS activ-
ity.21 Two prospective, nested case-control studies,
which collected serum prior to MS onset, showed
a significantly reduced risk of MS in those with
high 25(OH)D.22,23 Results from the current study
rule out the most plausible alternative (noncausal)
interpretations of these observational studies, thus
strengthening evidence of a causal link between 25
(OH)D and MS, even after accounting for other risk
factors and potential confounders.
Molecular studies also suggest that low serum 25
(OH)D may be a causal risk factor for MS. Studies
examining the location of vitamin D receptor–binding
sites (also known as vitamin D response elements or
VDREs) in the genome have shown that MS-
associated loci are substantially enriched for VDREs,
including in the promoter region of HLA-DRB1,24,25
and that VDREs are more often exposed in open chro-
matin regions in immune cells compared with non-
immune cells.26 These findings reinforce the
plausibility that vitamin D regulates genes that play
important roles in the development or progression of
MS. Furthermore, increased exposure to vitamin D
leads to changes in immune cells that lead to decreased
production of inflammatory cytokines, a decrease in
Th1 and Th17 cell differentiation, and an increase in
T regulatory cells, suggesting that low vitamin D is
acting on MS by shifting the balance of the immune
system toward a more proinflammatory state.27–29
The results of this study are in agreement with
another recent MR study that used summary-level
data only from the International Multiple Sclerosis
Genetics Consortium and showed a causal effect for
low 25(OH)D onMS risk.30 There is some data over-
lap between previous and current studies; specifically,
2,812 EIMS/GEMS participants included here were
also in the summary data analysis.30 However,
because individual-level data were not available for
the prior study, the authors were unable to control
for established genetic and environmental risk factors
associated with MS. Importantly, the current study
shows that measured variables did not contribute sub-
stantially to confounding of the causal relationship
between low 25(OH)D and MS risk. Furthermore,
the previous analysis relied on stronger assumptions30
compared with a traditional MR analysis as presented
in the current study. Finally, a CYP24A1 SNP
described in the previous report30 was not included
in our analysis, as it did not demonstrate association
Table 3 Results of mendelian randomization analysis for causal effect of
vitamin D in KPNC and EIMS/GEMS and the combined meta-analysis
result
Data set No. cases No. controls Causal odds ratio 95% CI p Value
KPNC 1,056 9,015 0.79 0.64–0.99 0.04
EIMS/GEMS 6,335 5,762 0.86 0.76–0.98 0.03
Meta-analysis 7,391 14,777 0.85 0.76–0.94 0.003
Abbreviations: CI 5 confidence interval; EIMS 5 Epidemiological Investigation of Multiple
Sclerosis; GEMS 5 Genes and Environment in Multiple Sclerosis; KPNC 5 Kaiser Perma-
nente in Northern California.
Values adjusted for matching variables (and study status in Swedish population), principal
component analysis/multidimensional scaling variables, presence of HLA-DRB1*15:01 al-
leles, a non-HLA multiple sclerosis genetic risk score, ever smoking, college education, and
BMI at age 18–20 years or in 20s. Full expanded models are shown in tables e-1 and e-2.
Table 4 Results of overidentification tests using
each 25(OH)D SNP as a separate IV
SNP used in IV Odds ratio 95% CI p Value
KPNC
rs2282679 0.94 0.84–1.05 0.26
rs2060793 0.92 0.83–1.02 0.11
rs3829251 0.93 0.81–1.06 0.27
EIMS/GEMS
rs2282679 0.99 0.93–1.06 0.80
rs10741657 0.92 0.87–0.97 0.002
rs3829251 0.84 0.79–0.90 ,0.0001
Abbreviations: CI 5 confidence interval; EIMS 5 Epidemio-
logical Investigation of Multiple Sclerosis; GEMS 5 Genes
and Environment in Multiple Sclerosis; IV 5 instrumental
variable; KPNC5 Kaiser Permanente in Northern California;
SNP 5 single nucleotide polymorphism.
Values adjusted for matching variables (and study status
in Swedish population), principal component analysis/
multidimensional scaling variables, presence of HLA-
DRB1*15:01 alleles, a non-HLA multiple sclerosis genetic
risk score, ever smoking, college education, and BMI at age
18–20 years or in 20s.
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with 25(OH)D at genome-wide significance,16 which
was among the criteria for SNPs to be included in our
IV for MR analysis. It is possible that the association
between a new IV that included the CYP24A1 SNP
and risk of MS might show a stronger magnitude of
effect. The number of SNPs that capture variation in
serum 25(OH)D levels is likely to grow as GWAS
become larger.
An MR study relies on the following assumptions
regarding the validity of the IV: (1) the genotype (IV)
is associated with the phenotype (25(OH)D levels),
(2) it is independent of measured or unmeasured con-
founders, and (3) it can only influence the outcome
via the causal effect of the exposure.20 We were able
to meet most model assumptions by using a 25(OH)
D IV established to be strongly associated with serum
25(OH)D in an independent population through
a large GWAS and testing whether the 25(OH)D
IV is independent of measured confounders. How-
ever, associations with unmeasured or unknown con-
founders cannot be ruled out, leaving one assumption
not fully testable.
Common reasons for violations of MR assump-
tions are population stratification, LD (between the
loci under study and other polymorphisms associated
with the outcome), pleiotropy, and developmental
canalization.2 The potential for population stratifica-
tion has been handled rigorously in the data analysis
stage, and it is unlikely that it has caused confounding
in our study. We have evaluated possible loci that
might be associated with the 25(OH)D SNPs and
with MS and have not found any basis for LD being
the explanation for our findings. Pleiotropy concerns
the possibility of polymorphisms having different bio-
logical effects that may influence the outcome
through other pathways than the one studied. To
our knowledge, the SNPs do not have other biological
effects than in vitamin D metabolism, with the excep-
tion of rs3892951, upstream of DHCR7, which plays
a role in cholesterol synthesis. Cholesterol metabo-
lism has been associated with MS, although the exact
mechanisms are not yet understood; a role for pleiot-
ropy cannot be excluded.31 On the other hand, the
SNPs are near genes that have a clear, biologically
plausible role in determining 25(OH)D levels. GC
codes for the vitamin D–binding protein, which trans-
ports vitamin D to target tissues; CYP2R1 converts
vitamin D to its main circulating form, 25(OH)D;
and DHCR7 converts 7-dehydrocholesterol, the com-
pound that is converted to vitamin D3 in the skin in
the presence of UV radiation, to cholesterol. In addi-
tion, a 2012 study evaluated SNPs in these 3 genes to
look for evidence of pleiotropic effects and found that
there were no associations with several biomarkers.32 A
study of 1,500 Danish MS patients found that SNPs
in GC and CYP2R1 have significant effects on 25
(OH)D levels, further indicating that variants in those
2 genes are affecting MS via serum vitamin D.33 Can-
alization refers to the buffering of the effects of genetic
variants against changing 25(OH)D levels; if this
effect is present, the association between the IV and
MS risk would be biased toward the null.
Strengths and limitations. Our study included non-
Hispanic whites, which limits the generalizability of
our findings. This limitation is particularly relevant
in light of recent findings indicating that 25(OH)D
levels may not be associated with MS in Hispanic
populations.34 We assume that the 3 alleles
associated with 25(OH)D levels in the previous
GWAS on Europeans are also associated with 25
(OH)D levels in our populations. However, we
were able to test this assumption in a subset of
2,077 EIMS participants for whom serum samples
were collected at the time of inclusion in the study:
a linear regression model adjusted for the same
confounders as the main analyses showed that the
IV was associated with 25(OH)D levels (p ,
0.0001) among MS cases and healthy controls.
Other limitations include the assumption of
linearity and the assumption that the 3 alleles used
to construct the IV have additive effects on 25(OH)D
levels. Furthermore, our analysis of severity was
restricted to a cross-sectional measure, the MSSS,
and models could not account for the use of
disease-modifying therapies. Additional studies
should aim to replicate findings, specifically in
populations of other races/ethnicities, and better
examine how specific 25(OH)D-related variants
might influence MS susceptibility and progressive
disease. The strengths of this MR study are that
results are very unlikely to be due to reverse
causation or confounded by unmeasured variables,
that we were able to adjust for genetic ancestry,
which could feasibly still confound the relationship
between 25(OH)D SNPs and MS, and that similar
results were found in 2 independent populations from
2 areas with different sunlight exposure levels.
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